UTILIZZO DEL MEDROSSI PROGESTERONE ACETATO IN PAZIENTI NEOPLASTICI IN FASE AVANZATA

Translated title of the contribution: Use of medroxy progesterone acetate in advanced cancer patients

G. Acampora, A. Cuomo, M. Del Giudice, G. Russo, T. Sarubbi, P. L. Viscidi

Research output: Contribution to journalArticlepeer-review

Abstract

The authors report their experiences about the use of medroxy progesterone acetate (MPA) in high doses in the palliative therapy of patients suffering from advanced cancer. The research was carried out on 120 patients no more capable to respond to any active therapy and only undergoing symptomatic treatment. The patients were treated for 12 weeks with MPA (1000 mg/die) and were weekly assessed for pain, cenaesthesia and, essentially, for quality of life. On the whole, the results emphasized a reduction of the painful syndrome, if present, an improvement of the psychological state and particularly of appetite, also by reason of the consequent reduced intake of analgesic and adjuvant drugs.

Translated title of the contributionUse of medroxy progesterone acetate in advanced cancer patients
Original languageItalian
Pages (from-to)75-78
Number of pages4
JournalGiornale Italiano di Oncologia
Volume14
Issue number2
Publication statusPublished - 1994

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Use of medroxy progesterone acetate in advanced cancer patients'. Together they form a unique fingerprint.

Cite this